Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea and Aspirin in Intermediate Risk Primary Thrombocythaemia
NCT00175838Phase 3Completed
- Sponsor
- University of Cambridge
- Start
- Jul 1997
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxyurea in essential thrombocythemia (ET) (3 arms), sponsored by University of Cambridge. Primary endpoint: Incidence of thrombosis and major haemorrhage at 14 years. Started Jul 1997; status: completed.
02
Drugs
hydroxyurea
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT00175838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175838.